MSD has announced a significant $9.2 billion acquisition of Cidara Therapeutics, marking its second major deal in 2025 as the company seeks to enhance its antiviral portfolio. This strategic buyout comes in the wake of Keytruda’s impending patent expiration, prompting MSD to invest heavily in innovative therapies that could sustain its market position.
The acquisition of Cidara is particularly noteworthy as it aligns with the growing demand for effective flu antivirals, especially in light of recent public health challenges. By integrating Cidara’s promising pipeline, MSD aims to bolster its offerings in infectious disease management, an area that has gained heightened attention from healthcare providers and regulators alike.
This move not only reflects MSD’s commitment to expanding its therapeutic capabilities but also underscores the competitive landscape of the pharmaceutical industry, where companies are increasingly focused on securing robust portfolios to navigate patent cliffs and evolving market needs.
Open the full market picture for your next decision →
